Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company Tuesday, including a restructuring of R&D and Japan operations. The pharma anticipates a decline in its FY19 core operating profit due to loss of exclusivity for key products

Read the full 511 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE